Home World News Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal... World News Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 294 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... January 19, 2021 Why haven’t we cured cancer? June 20, 2022 Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR... November 6, 2023 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 Load more HOT NEWS Running a cancer helpline in COVID-19: two years on the virtual... Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... Determining Fluid Requirements Annual Multicancer Early Detection Test Not Associated with a Lower Incidence...
